Zewei Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zewei Mao has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Chunping Wan
Yunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine, Kunming, China
18 shared publications Hui Gao
School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, 650500, PR China
15 shared publications- Ruirui Wang
College of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China
9 shared publications Xiao Zhang
Yunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine, Kunming, China
9 shared publicationsMinxin Li
School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, PR China
8 shared publicationsYanling Tang
School of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming 650500, P.R. China
8 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 11265-11267
Correction: New 1,2,3-triazole-linked (±)-agrimonolide derivatives as anti-ulcerative colitis agents inhibiting JAK1/STAT3 pathways
- 7 August 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 11265-11267
Open AccessCorrection: New 1,2,3-triazole-linked (±)-agrimonolide derivatives as anti-ulcerative colitis agents inhibiting JAK1/STAT3 pathways
- 10 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1621-1628
Vasicine-Based Synergistic Antifungal Agents against FLC-Resistant Candida albicans Targeting Ras/cAMP/PKA Pathway
A series of novel vasicine-based derivatives were designed and synthesized, and in vitro antifungal activities were evaluated. Most compounds showed synergistic antifungal effects with fluconazole (FLC) against FLC-resistant C. albicans. Compound 3n exhibited the best activity (MIC50 = 1.29 μM, FICI = 0.01) with no obvious cytotoxicity to 16HBE cells. Mechanistic studies revealed that 3n combined with FLC inhibited biofilm formation and efflux pump activity, and synergistically targeted the Ras/cAMP/PKA pathway to block yeast-to-hyphae transition. This dual mechanism provides a new strategy for treating FLC-resistant C. albicans infections.
- 10 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1621-1628
Vasicine-Based Synergistic Antifungal Agents against FLC-Resistant Candida albicans Targeting Ras/cAMP/PKA Pathway
A series of novel vasicine-based derivatives were designed and synthesized, and in vitro antifungal activities were evaluated. Most compounds showed synergistic antifungal effects with fluconazole (FLC) against FLC-resistant C. albicans. Compound 3n exhibited the best activity (MIC50 = 1.29 μM, FICI = 0.01) with no obvious cytotoxicity to 16HBE cells. Mechanistic studies revealed that 3n combined with FLC inhibited biofilm formation and efflux pump activity, and synergistically targeted the Ras/cAMP/PKA pathway to block yeast-to-hyphae transition. This dual mechanism provides a new strategy for treating FLC-resistant C. albicans infections.
- 27 April 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 178, 109910
Exploration of novel costunolide derivatives bearing indole/indoline as anti-ulcerative colitis agents by targeting JAK2-STAT3 pathways
- 27 April 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 178, 109910
Exploration of novel costunolide derivatives bearing indole/indoline as anti-ulcerative colitis agents by targeting JAK2-STAT3 pathways
- 21 November 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (3) , 4541-4554
Vasicine derivatives as potent MAPK inhibitors for psoriasis treatment
Psoriasis is a common polygenic hereditary skin disease and difficult to cure. Vasicine is an active alkaloid from Chinese herbal medicine Justicia adhatoda L. In present work, we have prepared a series of vasicine derivatives, and anti-inflammatory activities in vitro and in vivo have been evaluated. The in vitro results revealed that derivatives showed good anti-inflammatory activity of inhibiting NO generation. In vivo studies indicated that 4r could alleviate imiquimod induced skin inflammation, reduce the thickness of the epidermis and pathological lesions. Mechanism research showed that 4r could attenuate psoriasis-like skin inflammation via inhibiting MAPK signaling pathway activation, and alleviate LPS-induced inflammation in HaCat cells. Molecular docking study demonstrated that 4r could effectively bind to the active pocket of target MAPK protein 4U3Y and 5J5T. Therefore, vasicine derivatives may be considered as potent MAPK inhibitors for psoriasis treatment.
- 21 November 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (3) , 4541-4554
Vasicine derivatives as potent MAPK inhibitors for psoriasis treatment
Psoriasis is a common polygenic hereditary skin disease and difficult to cure. Vasicine is an active alkaloid from Chinese herbal medicine Justicia adhatoda L. In present work, we have prepared a series of vasicine derivatives, and anti-inflammatory activities in vitro and in vivo have been evaluated. The in vitro results revealed that derivatives showed good anti-inflammatory activity of inhibiting NO generation. In vivo studies indicated that 4r could alleviate imiquimod induced skin inflammation, reduce the thickness of the epidermis and pathological lesions. Mechanism research showed that 4r could attenuate psoriasis-like skin inflammation via inhibiting MAPK signaling pathway activation, and alleviate LPS-induced inflammation in HaCat cells. Molecular docking study demonstrated that 4r could effectively bind to the active pocket of target MAPK protein 4U3Y and 5J5T. Therefore, vasicine derivatives may be considered as potent MAPK inhibitors for psoriasis treatment.
- 18 November 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 167, 109253
Glycolysis-mediated energy metabolism mechanisms: Synergistic antifungal activity of (±)-methylagrimonolide against drug-resistant Candida albicans
- 18 November 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 167, 109253
Glycolysis-mediated energy metabolism mechanisms: Synergistic antifungal activity of (±)-methylagrimonolide against drug-resistant Candida albicans
- 6 November 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (3) , 4371-4383
Exploration of new azole derivatives containing ethanolamine moiety as anti-UC agents by inhibiting NF-κB/MAPK pathways
Ulcerative Colitis (UC) is a recurrent inflammatory bowel disease with a long and difficult treatment cycle. In this work, a series of new azole derivatives containing ethanolamine moiety have been prepared, and their anti-inflammatory activities were tested. The results indicated that ethanolamine moiety was beneficial for increasing the anti-inflammatory activity of azole derivatives, and most of them showed good inhibition of NO generation. In vivo experiments have shown that 7f could reduce the levels of TNF-α and IL-1β cytokines, significantly inhibit the phosphorylation level of p65 NF-κB, and down-regulate the phosphorylation of ERK and JNK on DSS-induced UC model. Therefore, these azole derivatives may be considered as new anti-UC agents by inhibiting NF-κB/MAPK signaling pathways. Graphic Abstract
- 6 November 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (3) , 4371-4383
Exploration of new azole derivatives containing ethanolamine moiety as anti-UC agents by inhibiting NF-κB/MAPK pathways
Ulcerative Colitis (UC) is a recurrent inflammatory bowel disease with a long and difficult treatment cycle. In this work, a series of new azole derivatives containing ethanolamine moiety have been prepared, and their anti-inflammatory activities were tested. The results indicated that ethanolamine moiety was beneficial for increasing the anti-inflammatory activity of azole derivatives, and most of them showed good inhibition of NO generation. In vivo experiments have shown that 7f could reduce the levels of TNF-α and IL-1β cytokines, significantly inhibit the phosphorylation level of p65 NF-κB, and down-regulate the phosphorylation of ERK and JNK on DSS-induced UC model. Therefore, these azole derivatives may be considered as new anti-UC agents by inhibiting NF-κB/MAPK signaling pathways. Graphic Abstract
- 31 October 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 166, 109181
Exploration of piperazine-azole hybrids as antifungal agents against drug-resistant Candida albicans
- 31 October 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 166, 109181
Exploration of piperazine-azole hybrids as antifungal agents against drug-resistant Candida albicans
- 23 September 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (3) , 4157-4170
New 1,2,3-triazole-linked (±)-agrimonolide derivatives as anti-ulcerative colitis agents inhibiting JAK1/STAT3 pathways
Ulcerative colitis (UC) is a chronic, nonspecific inflammatory bowel disease that is very difficult to cure. In this study, we have designed and synthesized a series of new 1,2,3-triazole-linked (±)-Agrimonolide derivatives and evaluated their anti-inflammatory activities. The in vitro results demonstrated that most triazole derivatives effectively inhibited NO production, and most compounds exhibited better anti-inflammatory activity than that of (±)-Agrimonolide and positive drug Dexamethasone. The further in vivo tests indicated that 6d could inhibit the release of inflammatory mediators in the colon tissue and alleviate Ulcerative colitis by inhibiting JAK1/STAT3 pathways.
- 23 September 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (3) , 4157-4170
New 1,2,3-triazole-linked (±)-agrimonolide derivatives as anti-ulcerative colitis agents inhibiting JAK1/STAT3 pathways
Ulcerative colitis (UC) is a chronic, nonspecific inflammatory bowel disease that is very difficult to cure. In this study, we have designed and synthesized a series of new 1,2,3-triazole-linked (±)-Agrimonolide derivatives and evaluated their anti-inflammatory activities. The in vitro results demonstrated that most triazole derivatives effectively inhibited NO production, and most compounds exhibited better anti-inflammatory activity than that of (±)-Agrimonolide and positive drug Dexamethasone. The further in vivo tests indicated that 6d could inhibit the release of inflammatory mediators in the colon tissue and alleviate Ulcerative colitis by inhibiting JAK1/STAT3 pathways.
- 13 August 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 130, 118351
(±)-Agrimonolide: Efficient synthesis and treatment of inflammatory bowel disease via JAK1/STAT3 pathway inhibition
- 13 August 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 130, 118351
(±)-Agrimonolide: Efficient synthesis and treatment of inflammatory bowel disease via JAK1/STAT3 pathway inhibition
- 22 January 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 156, 108200
N-Heterocyclic functionalized chalcone derivatives as anti-inflammatory agents for atopic dermatitis treatment by inhibiting JAK1/STAT3 signaling pathway
- 22 January 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 156, 108200
N-Heterocyclic functionalized chalcone derivatives as anti-inflammatory agents for atopic dermatitis treatment by inhibiting JAK1/STAT3 signaling pathway